SEC Form 4	
------------	--

П

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person [*] Hamilton Atlantic		rson [*]	2. Issuer Name and Ticker or Trading Symbol Genesis Biopharma, Inc [GNBP]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner
	(First) UR TRUST CO. I L PLACE, P.O. B		3. Date of Earliest Transaction (Month/Day/Year) 03/31/2010	Officer (give title Other (specify below)
(Street) GEORGE TOWN, GRAND GAYMAN	E9		4. If Amendment, Date of Original Filed (Month/Day/Year)	 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
(City)	(State)	(Zip)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock	03/31/2010	03/31/2010	J ⁽¹⁾		5,854,753	D	\$0 ⁽¹⁾	0	D		
Common Stock	03/31/2010	03/31/2010	J ⁽¹⁾		5,854,753	D	\$0 ⁽¹⁾	0	D		
Common Stock	03/31/2010	03/31/2010	J ⁽¹⁾		5,854,753	D	\$0 ⁽¹⁾	0	D		
Common Stock	03/31/2010	03/31/2010	J ⁽¹⁾		3,395,757	D	\$0 ⁽¹⁾	0	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Shares originally acquired by Reporting Person as consideration for transfer of certain intellectual property rights to Issuer as reported by Reporting Person in Schedule 13D filed by Reporting Person on March 26, 2010. Reporting Person subsequently distributed these Shares to its shareholders on pro-rata basis pursuant to Shareholder Distribution Agreement, as reflected in Table 1 of this Form 4. **Remarks:**

<u>/s/ Amy</u>	v Wang	

** Signature of Reporting Person

11/04/2010

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.